Table 3.
Baseline factors significantly associated with remission in each region*
| Variables | Adjusted OR | OR 95% CI | P-value |
|---|---|---|---|
| East Asia | |||
| Being older | 1.00 | 0.98–1.02 | 0.888 |
| Being male (versus female) | 1.00 | 0.70–1.42 | 0.983 |
| Higher CGI-S score | 0.68 | 0.50–0.94 | 0.021 |
| Any treatment/therapies for MDD in the past 24 months | 0.69 | 0.47–0.998 | 0.049 |
| Treatment with duloxetine (versus SSRI) | 2.58 | 1.77–3.76 | <0.001 |
| Middle East | |||
| Being older | 1.00 | 0.97–1.03 | 0.892 |
| Being male (versus female) | 1.83 | 0.98–3.40 | 0.058 |
| Higher QIDS-SR16 score | 0.88 | 0.81–0.95 | 0.002 |
| More MDD episodes in the past 24 months | 0.77 | 0.66–0.90 | <0.001 |
| Treatment with duloxetine (versus SSRI) | 2.78 | 1.66–4.66 | <0.001 |
| Mexico | |||
| Being older | 1.00 | 0.98–1.01 | 0.491 |
| Being male (versus female) | 1.29 | 0.91–1.84 | 0.157 |
| Higher QIDS-SR16 score | 0.90 | 0.86–0.93 | <0.001 |
| Having significant comorbidities | 0.63 | 0.46–0.87 | 0.004 |
| Treatment with duloxetine (versus SSRI) | 1.95 | 1.37–2.78 | <0.001 |
Notes:
*
Only significant factors are presented in this table, except for age and sex. This multiple regression included remission as a time-varying variable during follow-up, and was also adjusted for visit numbers.
Abbreviations: CI, confidence interval; OR, odds ratio; MDD, major depressive disorder; CGI-S, Global Impressions of Severity; QIDS-SR16, 16-item Quick inventory of Depressive Symptomatology Self-Report; SSRI, selective serotonin reuptake inhibitor.